Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FGFR3 - TACC3 |
Therapy | PD173074 |
Indication/Tumor Type | urinary bladder cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 - TACC3 | urinary bladder cancer | sensitive | PD173074 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Votrient (pazopanib) inhibited tumor growth in cell line xenograft models of bladder cancer harboring FGFR3-TACC3 (PMID: 23558953). | 23558953 |
PubMed Id | Reference Title | Details |
---|---|---|
(23558953) | Identification of targetable FGFR gene fusions in diverse cancers. | Full reference... |